Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on June 30, 2026. The filing details the entry into a Material Definitive Agreement regarding a private placement of securities. The transaction closed on July 1, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.0 million.
- Use of Proceeds: Working capital purposes.
- Securities Issued:
- 960,000 Pre-Funded Warrants (exercise price $0.0001).
- 960,000 Series C-1 Warrants (exercise price $3.00).
- 960,000 Series C-2 Warrants (exercise price $3.00).
- Combined Purchase Price: $3.1249 per Pre-Funded Warrant and accompanying Common Warrants.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Warrants: 62,400 Placement Agent Warrants (6.5% of Pre-Funded Warrant Shares) with an exercise price of $3.9063.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes and Agreements
The primary material change is the capital raise via a private placement priced at-the-market. Key contractual terms include:
- Lock-Up Agreements: Directors and officers are subject to a 60-day lock-up following the Effective Date.
- Issuance Restrictions: The Company agreed not to issue Common Stock or equivalents for 60 days post-Effective Date, with limited exceptions.
- Variable Rate Transaction Ban: Prohibited for one year, except for an at-the-market facility with H.C. Wainwright & Co., LLC after 60 days.
- Registration Rights: The Company must file a registration statement within 15 days and use reasonable efforts to make it effective within 45 days (or 75 days if reviewed).
- Liquidated Damages: If registration deadlines are missed, the Company must pay 1% of the aggregate investment per 30-day period, capped at 6%.
Outlook, Risks, and Contingencies
The Company intends to use net proceeds for working capital. The filing highlights standard risks associated with private placements, including the requirement for stockholder approval to exercise Series C-1 Warrants and the potential for dilution upon exercise of warrants. The Company is subject to customary indemnification obligations and termination provisions within the Purchase Agreement.
Investor Verification Checklist
- Verify the exact closing date and confirmation of fund receipt (stated as July 1, 2026).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Confirm the status of the registration statement for resale of Warrant Shares to ensure compliance with the 15-day filing deadline.
- Assess the dilution impact of the 2.88 million total warrant shares (960k Pre-Funded + 960k Series C-1 + 960k Series C-2) plus 62,400 Placement Agent Warrants.
- Check for any subsequent filings regarding stockholder approval required for Series C-1 Warrant exercise.